Next - generation kinase inhibitors

Search documents
Nuvation Bio Inc. (NUVB): A Bull Case Theory
Yahoo Finance· 2025-10-08 17:02
We came across a bullish thesis on Nuvation Bio Inc. on wallstreetbets subreddit by asagi_lumina. In this article, we will summarize the bulls’ thesis on NUVB. Nuvation Bio Inc.'s share was trading at $3.2200 as of September 23rd. AbCellera Biologics Inc. (ABCL) Appoints Chief Medical Officer Nuvation Bio (NUVB), founded in 2018 by David T. Hung, M.D., is an oncology biotech focused on next-generation kinase inhibitors targeting genetically defined cancers driven by aberrant kinase signaling. The company ...